CLDX stock news
This page provides real-time market news, earnings updates, and company announcements related to Celldex Therapeutics, Inc. (CLDX).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-02-28 07:28 EST
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile
Finviz2026-02-23 13:04:05
Stocks Poised for Lower Open as Tariff Concerns Linger; Investors Eye Nvidia Results and Key U.S. Economic Reports
101 finance2026-02-23 14:24:36
Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria.
老虎证券2026-02-25 12:22:33
Celldex: Fourth Quarter Financial Overview
101 finance2026-02-25 21:51:07
CLDX stock chart
CLDX stock detailsCLDX stock price change
On the last trading day, CLDX stock closed at 29.63 USD, with a price change of -3.31% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more